Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Founder of the Free From Fibroids Foundation Asks Important Question: Is Hysterectomy Obsolete For Uterine Fibroids?

Dr. John Lipman, the Founder of the Free From Fibroids Foundation, challenges the outdated practice of performing life-changing, unnecessary hysterectomy without first considering much safer, less expensive, and less invasive non-surgical options like Uterine Fibroid Embolization (UFE).


News provided by

Free From Fibroids Foundation

Sep 21, 2021, 10:35 ET

Share this article

Share toX

Share this article

Share toX

FreeFromFibroids.org
FreeFromFibroids.org

WASHINGTON, Sept. 21, 2021 /PRNewswire-PRWeb/ -- The founder of the Free From Fibroids Foundation, Dr. John Lipman shares his thoughts on why Congress must pass the bipartisan Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 (S. 2444/H.R. 2007) and why it's critical to empower women with information about all of their treatment options as they battle uterine fibroids.

Dr. Lipman's thoughts are below:

Sixty years ago, the civil rights icon Fannie Lou Hamer, who made famous the phrase "I'm sick and tired of being sick and tired," had a hysterectomy without her consent for the treatment of uterine fibroids. Mrs. Hamer shared her experience and coined the phrase "Mississippi Appendectomy," the forced sterilization of poor Black women under the pretext of treating other gynecological health issues.

A systemic failing in our healthcare system is causing women, mostly Black and women of color, to unnecessarily have their uterus removed through hysterectomy for the treatment of fibroids. The majority of these hysterectomies are not occurring because the women want to lose their uterus, it is because they are told by their physician that hysterectomy is their only option to end the suffering they have been dealing with for so many years.

Annually nearly 600,000 hysterectomies are performed, making it the second most common surgery performed in the United States, and fibroids are the number one reason for hysterectomy.

Hysterectomy should be an option of last resort for women suffering from fibroids.

Uterine fibroids are the most common pelvic tumor seen in women. These benign, non-cancerous growths of various sizes are made up of muscle fibers and connective tissue. Nearly two-thirds of women by age 50 are impacted by fibroids and Black women are diagnosed with fibroids nearly three times as frequently as white women.

While fibroids are typically not fatal, they often make women's lives miserable. Symptoms include horribly heavy and lengthy periods, monthly abdominal and pelvic pain, pressure from the enlarged, pregnant-appearing uterus, and increased urinary frequency.

One aggressive driver of the excessive number of unnecessary hysterectomies for uterine fibroids is the significant resources and influence that the pharmaceutical and surgical device manufacturers have on physicians and hospitals to perpetuate this "status quo" of hysterectomy.

I see patients every day who are suffering from fibroids and don't want a hysterectomy. They simply want their life back. Hysterectomies take away a woman's ability to bear children, but also do more to a woman's body after the surgical wounds heal.

It's time to challenge the outdated practice of performing life-changing, unnecessary hysterectomy without first considering much safer, less expensive, and less invasive non-surgical options like Uterine Fibroid Embolization (UFE).

With a 25-year track record of safety and efficacy, UFE is performed by medical specialists known as interventional radiologists, is covered by Medicare, Medicaid, and commercial insurance, and is endorsed by the American College of Obstetricians & Gynecologists.

In marked contrast to hysterectomy, women choosing UFE undergo a brief outpatient procedure and are discharged home the same day with just a Band-Aid. Most importantly, women are able to keep their uterus.

Congress has an opportunity to help in this fight against fibroids and unnecessary hysterectomies and take an important step toward empowering and supporting women by passing the bipartisan Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2021 (S. 2444/H.R. 2007). This overdue legislation will provide research to try to find out where fibroids come from and how to prevent them and best treat them.

                                                                                        ###

About the author:

Dr. John Lipman is a board-certified Interventional Radiologist and renowned authority in the non-surgical treatment of uterine fibroids. He is the founder and chairman of the Free From Fibroids Foundation and the Fibroid Coalition.

Dr. Lipman is the President & CEO of the Atlanta Fibroid Center and is also an Adjunct Clinical Assistant Professor in the Department of Obstetrics & Gynecology at Morehouse School of Medicine. Learn more about Dr. Lipman's work with the Free From Fibroids Foundation at freefromfibroids.org.

Media Contact

Dr. John Lipman, Free From Fibroids Foundation, +1 (202) 552-1708, [email protected]

SOURCE Free From Fibroids Foundation

Related Links

https://freefromfibroids.org/

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.